Fred Hutchinson Cancer Research Center is at the forefront of a fundamental shift in how cancer is treated and cured. At Fred Hutch, PICI researcher Philip Greenberg, MD, develops new ways to empower a patient’s immune system to eradicate cancer. With PICI, he uses mouse models to characterize and test translatable strategies to treat many cancers. He also develops more effective T-cells to treat ovarian cancer through adoptive cell therapy. Tijana Martinov, PhD, a Parker Scholar in Greenberg’s lab, designs and tests T-cells that target and destroy multiple myeloma in mouse models. Philip Greenberg, MD | Investigator Tijana Martinov, PhD | Parker Scholar Related Research Focus CAR-T and Cell Therapy: The Next Wave Announcement, Press Release Funding the Future of Cancer Research Announcement, Press Release Alliance Aims to Develop Next-Gen Cancer Therapies Announcement, Press Release Biomarkers May Predict Better Treatment Options Announcement, Press Release First Patients Dosed in Pancreatic Platform Trial Partner Highlight Connecting Patients with Innovative Immunotherapies Our Impact, Partner Highlight All the Right Ingredients: The Founders of ArsenalBio Partner Highlight, Press Release NanoString and PICI Partner to Optimize Cell Therapies Announcement, Research Update Five Key Takeaways from ASCO 2021